CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 10 enrolled
Drug / intervention
ATM FOG in PDdrug
Likely dose
ATM FOG in PD 40mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03651856
NCT03651856Phase 3Completed
CompareCT.gov

A Pilot Study of Atomoxetine for Freezing of Gait in Parkinson's Disease

Medical University of South Carolina·interventional·Posted Aug 29, 2018·Updated Nov 28, 2018

In Brief

A Phase 3 clinical trial evaluating ATM FOG in PD for Parkinson's Disease and Freezing of Gait. Completed, enrolled 10 participants across 1 site.

Detailed Summary

Subjects are being asked to participate in this study to determine the safety and effectiveness of a drug called atomoxetine in the treatment of freezing of gait for Parkinson's Disease patients. Atomoxetine (ATM) is an approved drug currently on the market for the treatment of attention deficit. It works to increase the amount of norepinephrine (a chemical in the brain that helps keep us awake and alert) in our brain. ATM has not been approved by the Food and Drug Administration (FDA) to be used in the treatment of PD, but has been found to be well tolerated in this patient population.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease, Freezing of Gait
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 29, 2018
Enrollment StartJan 1, 2013
Primary CompletionFeb 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 7.8 years ago

Interventions

ATM FOG in PDdrug

open label pilot study on atomoxetine 40mg BID on patients with Parkinson's disease and Freezing of Gait